Charles River Laboratories International, Inc. (CRL:NYSE) closed at $345.37 on October 23, 2026, up 1.68% on the day. The stock trades 1.7% below its 52-week high of $351.21 and 136.2% above its 52-week low of $146.20. Over the past year, it gained 75.3%. Charles River Laboratories International, Inc. is part of the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch).
In 252 trading sessions since October 23, 2025, CRL closed higher on 131 days (52%). Its best day was August 5, 2026 (+11.36%) and its worst was March 12, 2026 (-9.62%). The stock moved 10% or more in a single session 2 times. It opened at least 5% above the previous day's high 2 times.
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery and development services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily genetically and microbiologically defined purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening preclinical drug candidates comprising genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for identification of a druggable target through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, which comprise bioanalysis, pharmacokinetics, drug metabolism, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-steril...
Find more stocks like CRL with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.